At a glance
ClinicalIndex Comparison RecordPhase 2Active· 80 enrolled
Drug / intervention
Arsenic Trioxidedrug
Likely dose
Arsenic Trioxide 0.16mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Research on Efficacy and Safety of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma：A Prospective，Single-arm, Open-label, Multi-center Study
In Brief
A Phase 2 clinical trial evaluating Arsenic Trioxide for Neuroblastoma. Active but no longer recruiting, targeting 80 participants across 1 site.
Detailed Summary
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroblastoma
CountriesChina
Collaborators--
Timeline
Phase 2Active
201820192020202120222023202420252026202720282029
Enrollment StartJun 2017
First PostedApr 2018
Primary CompletionAug 2023
TodayJul 2026
Study CompletionDec 2028
First PostedApr 20, 2018
Enrollment StartJun 12, 2017
Primary CompletionAug 30, 2023
Study CompletionDec 30, 2028
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 8.2 years ago
Interventions
Arsenic Trioxidedrug
Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.